![NVS-CECR2-1 rlukast Smiles: [2H]C([2H])([2H])OC(=O)NC1NC2=CC(=CC=C2N=1)S(=O)CCC](https://cdn.shopify.com/s/files/1/0389/1897/9723/products/M23629_1635914499.gif?v=1635914500)
Pay in 4 interest-free payments of $30.00 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Smiles: [2H]C([2H])([2H])OC(=O)NC1NC2=CC(=CC=C2N=1)S(=O)CCC
Only mutant p53-bearing tumors in the ReACp53-treated mice cohorts are 80-90% smaller in weight than the control cohort
2-b]pyrano[2''
MDA19 has potential for alleviating neuropathic pain without producing adverse effects in the central nervous system
RG-12915 is a selective 5-HT3 antagonist
NVS-CECR2-1 rlukast Smiles: [2H]C([2H])([2H])OC(=O)NC1NC2=CC(=CC=C2N=1)S(=O)CCCNVS CECR2 1, a non BET family Bromodomain (BRD) inhibitor, is a potent and selective cat eye syndrome chromosome region, candidate 2 (CECR2) inhibitor. NVS CECR2 1 binds to CECR2 BRD with high affinity (IC50=47 nM; KD=80 nM). NVS CECR2 1 exhibits cytotoxic activity and induces apoptosis against various cancer cells by targeting CECR2 as well as via CECR2 independent mechanism. Product information CAS Number: 1992047 61 6 Molecular Weight: 495. 68
US$ 126.47
US$ 188.89
US$ 112.23
US$ 123.31
US$ 190.05
US$ 10.00
US$ 197.09
US$ 310.82
US$ 399.50
US$ 15.00
US$ 123.31
US$ 188.89
US$ 126.47
US$ 394.19